Activation of FXR Suppresses Esophageal Squamous Cell Carcinoma Through Antagonizing ERK1/2 Signaling Pathway

References

• Huang FL, Yu SJ. Esophageal cancer: risk factors, genetic association, and treatment. Asian J Surg. 2016;41(3):S1015958416302019. doi:10.1016/j.asjsur.2016.10.005
   Web of Science ®Google Scholar
• Cristina B, Fabio L, Jacques F, et al. Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer. 2010;122(5):1118–1129.
   Web of Science ®Google Scholar
• Reid BJ, Barrett MT, Galipeau PC, et al. Barrett’s esophagus: ordering the events that lead to cancer. Eur J Cancer Prevent. 1996;5 Suppl 2(Supplement2):57. doi:10.1097/00008469-199612002-00009
   PubMed Web of Science ®Google Scholar
• Prateek S, Kenneth MQ, John D, et al. A critical review of the diagnosis and management of Barrett’s esophagus: the AGA Chicago Workshop. Gastroenterology. 2004;127(1):310–330. doi:10.1053/j.gastro.2004.04.01015236196
   PubMed Web of Science ®Google Scholar
• Hiroyuki K, Masanobu N. Treatments for esophageal cancer: a review. Gen Thorac Cardiovasc Surg. 2013;61(6):330–335. doi:10.1007/s11748-013-0246-023568356
   PubMedGoogle Scholar
• Marie C, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 2011;75(1):50–83.21372320
   PubMed Web of Science ®Google Scholar
• Cicenas J, Zalyte E, Rimkus A, Dapkus D, Noreika R, Urbonavicius S. JNK, p38, ERK, and SGK1 Inhibitors in Cancer. Cancers. 2017;10(1). doi:10.3390/cancers10010001
   PubMed Web of Science ®Google Scholar
• Qin Y, Hu Q, Ji S. et al. Homeodomain-interacting protein kinase 2 suppresses proliferation and aerobic glycolysis via ERK/cMyc axis in pancreatic cancer. Cell Prolif;2019. e12603. doi: 10.1111/cpr.1260330932257
   PubMed Web of Science ®Google Scholar
• Yin H, Yang X, Gu W, et al. HMGB1-mediated autophagy attenuates gemcitabine-induced apoptosis in bladder cancer cells involving JNK and ERK activation. Oncotarget. 2017;8(42):71642–71656. doi:10.18632/oncotarget.1779629069735
   PubMedGoogle Scholar
• Yanchun M, Yi W, Lu W, et al. Triptolide prevents proliferation and migration of Esophageal Squamous Cell Cancer via MAPK/ERK signaling pathway. Eur J Pharmacol. 2019;851:43–51. doi:10.1016/j.ejphar.2019.02.03030779917
   PubMed Web of Science ®Google Scholar
• Wang YD, Chen WD, Moore DD, Huang W. FXR: a metabolic regulator and cell protector. Cell Res. 2008;18(11):1087–1095.18825165
   PubMed Web of Science ®Google Scholar
• Wang YD, Yang F, Chen WD, et al. Farnesoid X receptor protects liver cells from apoptosis induced by serum deprivation in vitro and fasting in vivo. Mol Endocrinol. 2008;22(7):1622–1632. doi:10.1210/me.2007-052718436567
   PubMedGoogle Scholar
• Wang YD, Chen WD, Li C, et al. Farnesoid X receptor antagonizes JNK signaling pathway in liver carcinogenesis by activating SOD3. Mol Endocrinol. 2015;29(2):322–331. doi:10.1210/me.2014-122525496033
   PubMedGoogle Scholar
• Wang YD, Chen WD, Huang W. FXR, a target for different diseases. Histol Histopathol. 2008;23(5):621–627. doi:10.14670/HH-23.62118283647
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen W, M, Yu D, Forman B, Huang W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology. 2008;48(5):1632–1643. doi:10.1002/hep.2251918972444
   PubMed Web of Science ®Google Scholar
• Barone I, Vircillo V, Giordano C, et al. Activation of Farnesoid X Receptor impairs the tumor-promoting function of breast cancer-associated fibroblasts. Cancer Lett. 2018;437:89–99. doi:10.1016/j.canlet.2018.08.02630176263
   PubMed Web of Science ®Google Scholar
• Liu HM, Liao JF, Lee TY. Farnesoid X receptor agonist GW4064 ameliorates lipopolysaccharide-induced ileocolitis through TLR4/MyD88 pathway related mitochondrial dysfunction in mice. Biochem Biophys Res Commun. 2017;490(3):841–848. doi:10.1016/j.bbrc.2017.06.12928647362
   PubMed Web of Science ®Google Scholar
• Liu Y, Binz J, Numerick MJ, et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest. 2003;112(11):1678–1687. doi:10.1172/JCI1894514623915
   PubMed Web of Science ®Google Scholar
• Guo F, Xu Z, Zhang Y, et al. FXR induces SOCS3 and suppresses hepatocellular carcinoma. Oncotarget. 2015;6(33):34606–34616. doi:10.18632/oncotarget.531426416445
   PubMedGoogle Scholar
• Zhang Q, Su J, Wang Z, et al. MicroRNA-149* suppresses hepatic inflammatory response through antagonizing STAT3 signaling pathway. Oncotarget. 2017;8(39):65397–65406. doi:10.18632/oncotarget.1854129029439
   PubMedGoogle Scholar
• Wang YD, Chen WD, Yu D, Forman BM, Huang W. The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-kappaB) in mice. Hepatology (Baltimore, Md). 2011;54(4):1421–1432. doi:10.1002/hep.24525
   PubMed Web of Science ®Google Scholar
• Guo C, Qi H, Yu Y, et al. The G-Protein-Coupled Bile Acid Receptor Gpbar1 (TGR5) Inhibits Gastric Inflammation Through Antagonizing NF-kappaB Signaling Pathway. Front Pharmacol. 2015;6:287. doi:10.3389/fphar.2015.0028726696888
   PubMed Web of Science ®Google Scholar
• Pathak P, Xie C, Nichols RG, et al. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism. Hepatology (Baltimore, Md). 2018;68(4):1574–1588. doi:10.1002/hep.29857
   PubMed Web of Science ®Google Scholar
• Jiang Y, Iakova P, Jin J, et al. Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer. Hepatology. 2013;57(3):1098–1106. doi:10.1002/hep.2614623172628
   PubMed Web of Science ®Google Scholar
• Huang XF, Zhao WY, Huang WD. FXR and liver carcinogenesis. Acta Pharmacol Sin. 2015;36(1):37–43. doi:10.1038/aps.2014.11725500874
   PubMed Web of Science ®Google Scholar
• Peng Z, Chen J, Drachenberg CB, Raufman JP, Xie G. Farnesoid X receptor represses matrix metalloproteinase 7 expression, revealing this regulatory axis as a promising therapeutic target in colon cancer. J Biol Chem. 2019. doi:10.1074/jbc.RA118.004361
   Web of Science ®Google Scholar
• Gadaleta RM, Garcia-Irigoyen O, Moschetta A. Bile acids and colon cancer: is FXR the solution of the conundrum? Mol Aspects Med. 2017;56:66–74. doi:10.1016/j.mam.2017.04.00228400119
   PubMed Web of Science ®Google Scholar
• Wu PL, Zeng C, Zhou YF, Yin L, Yu XL, Xue Q. Farnesoid X Receptor Agonist GW4064 Inhibits Aromatase and ERbeta Expression in Human Endometriotic Stromal Cells. Reprod Sci. 2018. doi:10.1177/1933719118808912
   Web of Science ®Google Scholar
• Di Matteo S, Nevi L, Costantini D, et al. The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma. PLoS One. 2019;14(1):e0210077. doi:10.1371/journal.pone.021007730677052
   PubMed Web of Science ®Google Scholar
• Comeglio P, Filippi S, Sarchielli E, et al. Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model. J Endocrinol Invest. 2019.
   Web of Science ®Google Scholar
• Ferrell JM, Pathak P, Boehme S, Gilliland T, Chiang JYL. Deficiency of both farnesoid X receptor and Takeda G protein-coupled receptor 5 exacerbated liver fibrosis in mice. Hepatology (Baltimore, Md). 2019. doi:10.1021/jacs.5b09974
   PubMed Web of Science ®Google Scholar
• Guan B, Li H, Yang Z, Hoque A, Xu X. Inhibition of farnesoid X receptor controls esophageal cancer cell growth in vitro and in nude mouse xenografts. Cancer. 2013;119(7):1321–1329.23280144
   PubMed Web of Science ®Google Scholar
• De Gottardi A, Dumonceau JM, Bruttin F, et al. Expression of the bile acid receptor FXR in Barrett’s esophagus and enhancement of apoptosis by guggulsterone in vitro. Mol Cancer. 2006;5:48. doi:10.1186/1476-4598-5-4817054793
   PubMed Web of Science ®Google Scholar
• Tibbitt MW, Dahlman JE, Langer R. Emerging Frontiers in Drug Delivery. J Am Chem Soc. 2016;138(3):704–717.26741786
   PubMed Web of Science ®Google Scholar
• Sun Y, Liu WZ, Liu T, Feng X, Yang N, Zhou HF. Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. J Recept Signal Transduct Res. 2015;35(6):600–604. doi:10.3109/10799893.2015.103041226096166
   PubMed Web of Science ®Google Scholar
• Honda M, Kanno T, Fujita Y, Gotoh A, Nakano T, Nishizaki T. Mesothelioma cell proliferation through autocrine activation of PDGF-betabeta receptor. Cell Physiol Biochem. 2012;29(5–6):667–674. doi:10.1159/00017638622613967
   PubMed Web of Science ®Google Scholar
• Ragusa M, Statello L, Maugeri M, et al. Specific alterations of the microRNA transcriptome and global network structure in colorectal cancer after treatment with MAPK/ERK inhibitors. J Mol Med. 2012;90(12):1421–1438. doi:10.1007/s00109-012-0918-822660396
   PubMed Web of Science ®Google Scholar
• Said AH, Raufman JP, Xie G. The role of matrix metalloproteinases in colorectal cancer. Cancers. 2014;6(1):366. doi:10.3390/cancers601036624518611
   PubMed Web of Science ®Google Scholar
• Lu L, Ma GQ, Liu XD, et al. Correlation between GDF15, MMP7 and gastric cancer and its prognosis. Eur Rev Med Pharmacol Sci. 2017;21(3):535–541.28239815
   PubMed Web of Science ®Google Scholar
• Zhang Q, Liu S, Parajuli KR, et al. Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition. Oncogene. 2017;36(5):687–699. doi:10.1038/onc.2016.24027375020
   PubMed Web of Science ®Google Scholar
• Lian F, Xing X, Yuan G, et al. Farnesoid X receptor protects human and murine gastric epithelial cells against inflammation-induced damage. Biochem J. 2011;438(2):315–323. doi:10.1042/BJ2010209621619550
   PubMed Web of Science ®Google Scholar